David J. Arthur - Mar 3, 2022 Form 4 Insider Report for Salarius Pharmaceuticals, Inc. (SLRX)

Role
Chief Executive Officer, Director
Signature
/s/Mark Rosenblum, as Attorney-in-Fact
Stock symbol
SLRX
Transactions as of
Mar 3, 2022
Transactions value $
$54,540
Form type
4
Date filed
3/9/2022, 03:01 PM
Previous filing
Jan 21, 2022
Next filing
May 5, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction SLRX Common Stock Purchase $54.5K +139K +126.59% $0.39 250K Mar 3, 2022 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The Registrant issued these shares to the reporting person as part of his bonus; which shares were issued in lieu of net cash compensation. The shares were issued at the fair market value of the Registrants common stock on the date of grant.